Spark Investment Management’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Spark Investment Management’s Portfolio ECYT Stock Details ECYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-57,200	Closed	-$244K	–	811
2017 Q4	$244K	Sell	57,200 -119,500	-68%	-$569K	0.01%	545
2017 Q3	$249K	Buy	176,700 +58,400	+49%	+$81.4K	0.01%	578
2017 Q2	$177K	Buy	+118,300	New	+$254K	0.01%	675
2016 Q4	–	Sell	-74,610	Closed	-$230K	–	956
2016 Q3	$230K	Sell	74,610 -42,290	-36%	-$132K	0.02%	642
2016 Q2	$375K	Buy	116,900 +600	+0.5%	+$2.2K	0.04%	516
2016 Q1	$360K	Hold	116,300	–	–	0.04%	515
2015 Q4	$466K	Buy	+116,300	New	+$536K	0.06%	390
2015 Q1	–	Sell	-35,600	Closed	-$223K	–	801
2014 Q4	$223K	Buy	+35,600	New	+$217K	0.04%	470
2013 Q4	–	Sell	-86,200	Closed	-$1.15M	–	736
2013 Q3	$1.15M	Sell	86,200 -31,400	-27%	-$496K	0.26%	116
2013 Q2	$1.53M	Buy	+117,600	New	+$1.59M	0.41%	63

Other funds holding ECYT

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

GTC

Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

Spark Investment Management's ECYT Position: Q1 2018 in Review

Spark Investment Management sold out of Endocyte, Inc. Common Stock (ECYT) in Q1 2018, closing a stake of 57,200 shares — an estimated $244K sold.

Spark Investment Management first reported a position in ECYT in Q2 2013 and held it in 10 quarters. The position peaked at $1.53M in Q2 2013. 89 funds tracked by Wall St. Rank hold ECYT as of Q1 2018.

Spark Investment Management reported no remaining Endocyte, Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
Spark Investment Management sold 57,200 Endocyte, Inc. Common Stock shares in Q1 2018, an estimated $244K.
Spark Investment Management first reported a position in Endocyte, Inc. Common Stock in Q2 2013 and held it in 10 quarters.
Spark Investment Management's Endocyte, Inc. Common Stock position peaked at $1.53M in Q2 2013.
89 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q1 2018.

Based on Spark Investment Management's 13F filing for Q1 2018, filed 10 May 2018.